



**PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES
January 10, 2017**

The meeting was called to order at approximately 1:29 p.m. on Tuesday January 10, 2017.

Committee members present: Irina Petty, PA-C; Jennifer Rudell, R.Ph.; Robert Zaayer, PA-C; Nancy Ivanssek, PA-C; Curtis Gingrich, M.D., and Donald Roberts.

Staff members present: Sallie Debolt, and Cathy Hacker.

Guest: Beth Adamson, OAPA.

I. Review of the December 13, 2016 minutes:

Ms. Ivanssek moved to approve the minutes. Ms. Petty seconded the motion. All members voted aye. The motion carried.

II. Negative Formulary discussion

Ms. Debolt reminded the committee that in order to have a negative formulary it would require a statute and rule change as the current language says that we will show drugs that the PA may prescribe.

Mr. Zaayer stated that the new formulary should only show the may not and the PI categories.

Dr. Gingrich stated that he likes the way the Nursing Board formulary looks and that it is more user friendly. He further stated that new drugs to the market will be the CTP may prescribe until the PAPC categorizes them as CTP may not prescribe. Ms. Ivanssek and Ms. Debolt stated that this could be problematic.

Ms. Adamson stated that the OAPA wants all medications in the PI category to be moved to the CTP may prescribe category. She further stated that she would talk to the OAPA committee at their next meeting to start working on how the new formulary should look.

Ms. Ivanssek stated that the "in accordance with the SCA" category is going away in the nurse's formulary and feels that the PA formulary should be the same.

Dr. Gingrich and Mr. Zaayer both agreed that we need to keep the patients in mind when creating the formulary.

Ms. Ivanssek noted that it needs to be easy for the pharmacists as well. The committee agreed that this will be a difficult task to make this workable for all involved.

III. New Business

Ms. Debolt handed out the travel reimbursement forms to members that need to be attached to their financial disclosure forms that are due by May 15th.

The Physician Assistant Policy Committee meeting was adjourned by Mr. Zaayer at approximately 2:15 p.m. on Tuesday, January 10, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on January 10, 2017.

Robert Zaayer, PA-C, Chair, PAPC



**Physician Assistant Policy Committee minutes
May 9, 2017**

The meeting was called to order at approximately 1:47 p.m. on Tuesday May 9, 2017.

Committee members present: Irina Petty, PA-C; Megan Keller, R.Ph.; Megan Marchal, R.Ph.; Kindra Engle, D.O.; Robert Zaayer, PA-C; Nancy Ivansek, PA-C; Curtis Gingrich, M.D., and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, and Cathy Hacker.

Guest: Mandi Grandjean, OAPA.

I. Review of the January 10, 2017 minutes:

Dr. Gingrich moved to approve the minutes. Ms. Ivansek seconded the motion. Dr. Steinbergh abstained. All other members voted aye. The motion carried.

Ms. Ivansek noted that the formulary organization needs to be easy for the pharmacists as well. The committee agreed that this will be a difficult task to make this workable for all involved.

II. Formulary Review

The committee reviewed the following new drugs to the market, as listed in Facts and Comparison, and recommended the following categories for these medications.

- Lartruvo Antineoplastic Agent was added as a may not as all antineoplastic agents are currently in the CTP may not prescribe category.
- Zinplava was added as a miscellaneous GI drugs under the physician initiated/consultation.
- Intrarosa was tabled as is not yet available on the market.
-
- Eucrisa was added in the Anti-inflammatory section as a CTP may prescribe.
-
- Spinraza it was noted that this medication is similar to Xondys and that is already in the miscellaneous Neurologic Agents as a CTP may not prescribe.
-
- Trulance was added as a miscellaneous GI drugs under as a CTP may prescribe

Dr. Steinbergh moved to approve these changes to the formulary. Ms. Ivansek seconded the motion. All members voted aye. The motion carried.

The committee then reviewed the requests from Dr. Jeremy Groll to reclassify the following medications.

He requests to move **Femara** from the PI category to CTP may prescribe category as it is commonly used for ovulation induction. The committee decided to maintain it as Physician Initiated as PA's are not able to prescribe antineoplastic agents and the proposed use is off-label.

- He requests to move **Cabergoline** from the CTP may not prescribe category to CTP may prescribe category as it is commonly used for hyperprolactinemia. The committee moved this to the PI category as it is used in all types of practice specialties.
- He requests to move **Ganirelix** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. This was moved to the PI category.
- He requests to move **Cetrorelix** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. This was moved to the PI category.
- He requests to move **Somatropin** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. The committee left this in the CTP may not prescribe as this request is for off label use.
- He requests to move **Leuprolide** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. The committee left this in the CTP may not prescribe as this request is for off label use.

The committee referred the buprenorphine conversation to the PA/Scope of practice committee for their input.

Dr. Steinbergh moved to approve the above changes to the formulary. Ms. Keller seconded the motion. All members voted aye. The motion carried.

III. Rules review

The committee reviewed proposed rules 4731-11-01, 4731-11-02 and 4731-11-13, which are proposed as applicable to prescribing for acute pain. No comments were made.

The committee also reviewed proposed rules 4731-28-02, 4731-28-03, 4731-28-04 and 4731-28-05, which are proposed to establish a confidential monitoring program for all licenses. The committee had no comments.

IV. New business

No new business was discussed.

The Physician Assistant Policy Committee meeting was adjourned by Mr. Zaayer at approximately 3:22 p.m. on Tuesday, May 9, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on May 9, 2017.

Robert Zaayer, PA-C, Chair, PAPC



PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES

July 11, 2017

The meeting was called to order at approximately 1:37 p.m. on Tuesday July 11, 2017.

Committee members present: Kindra Engle, D.O.; Robert Zaayer, PA-C; Scott Cackler, PA-C; Curtis Gingrich, M.D., and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, and Cathy Hacker.

Guest: Mandi Grandjean, OAPA, Beth Adamson, OAPA, Greg Lestini, OAPA.

I. [Review of the May 9, 2017 minutes:](#)

Dr. Steinbergh moved to approve the minutes. Dr. Gingrich seconded the motion. All other members voted aye. The motion carried.

Dr. Steinbergh moved to elect Dr. Gingrich as the Chair of the PAPC. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

Dr. Steinbergh stated that she would like to elect a Co-Chair but would wait until we have a full quorum to discuss that.

II. **Formulary Review**

The committee was unable to review the medications due to lack of quorum.

III. **Rules review**

Sallie informed the committee that Rule 4731-1-06 allows PA's to obtain CE by providing free medical care to the indigent and uninsured. She stated that the NCCPA will accept these CE as well. These rules are being filed with CSI for review.

IV. **New business**

Dr. Steinbergh stated that the current formulary is ineffective and not working and that the committee needs to move forward with approving a negative formulary. She stated that only medications that the PA cannot prescribe will appear on the formulary. She further stated that she feels PA's should not be compared to NP's. She went on to say that the PAPC committee is ineffective and that she feels it should be dissolved and allow the Boards PA/Scope of practice committee to make the decisions for the PA practice.

Dr. Steinbergh requested that Dr. Gingrich and Ms. Debolt work together to find a better date for the committee to meet. The date that we currently meet interferes with the pharmacy board meeting and thus does not allow for the pharmacist members to attend.

Dr. Gingrich stated that he feels the committee could be useful if they managed the formulary faster. He stated that rarely is there a disagreement on where the medications are placed. He further stated that there needs to be a discussion to take into account PA's that are working in a hospital setting.

Sallie informed the members that starting with the October 2017 meeting they will no longer be paid a per diem for their service. They will be paid for their travel. She further stated that they will no longer be required to complete the financial disclosure statements.

The Physician Assistant Policy Committee meeting was adjourned by Dr. Gingrich at approximately 2:44 p.m. on Tuesday, July 11, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on July 11, 2017.

Curtis Gingrich, MD, Chair, PAPC



PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES

August 8, 2017

The meeting was called to order at approximately 1:34 p.m. on Tuesday August 8, 2017.

Committee members present: Donald Roberts, Robert Zaayer, PA-C; Scott Cackler, PA-C; Curtis Gingrich, M.D., Joshua Cox, R.Ph.; and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, and Cathy Hacker.

Guest: Mandi Grandjean, OAPA, Beth Adamson, OAPA, Greg Lestini, OAPA.

I. [Review of the July 11, 2017 minutes:](#)

Dr. Steinbergh moved to approve the minutes. Mr. Cackler seconded the motion. All other members voted aye. The motion carried.

Ms. Debolt stated that there was an omission in the March 2016 minutes. It was requested that the March 2016 PAPC minutes be amended to reflect that the committee reviewed rule 4731-21 and recommended it for filing at CSI.

II. **Formulary Review**

The committee recommended that PA's be able to order Buprenorphine for administration in a hospital setting without the data waiver for use other than for opioid dependency.

Dr. Steinbergh moved to approve this change. Mr. Cackler seconded the motion. All members voted aye. The motion carried.

The committee discussed where Zinplava was placed in the formulary under the miscellaneous GI agents. Mr. Zaayer and Dr. Gingrich both agreed that the listing of this medication under the miscellaneous GI agents indicates its accepted use and does not limit PA usage to those within a GI specialty. Therefore there is no need to alter the current formulary. No change was made to the formulary.

It was brought to the committee's attention that Taltz was on the formulary but not Cosentyx. Mr. Cox noted that this is a Biological response modifier and but one example of this class of medication. He recommended to add anti psoriatic monoclonal antibodies category and that this would cover all psoriatic medications.

Dr. Steinbergh moved to add the category anti psoriatic monoclonal antibodies to the formulary in the physician initiated category. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The committee then reviewed the request from Cleveland Clinic requesting that Immune-Suppressants; Immune-modulators; Interferon; Monoclonal antibodies; and potassium channel blockers all be moved to the CTP holder may prescribe category from the CTP may not and the PI category. Dr. Steinbergh wants them all to be PI by protocol in a hospital setting. Mr. Cackler agreed, however, he stated that some of these medications can be used

for other purposes and should be in the PI category. Mr. Cox noted that Xgeva was in the wrong category on the formulary.

Dr. Steinbergh moved to put all of these medications in the PI/Consult category and to add that in a neurologist practice only. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The request by Caitlin Jones for clarification for the use of HCG while practicing in a physical medicine practice was reviewed. The rationale for utilization of this medication after review of its approved indications was not clear.

Dr. Steinbergh moved to table this request and ask for clarification of what the HCG hormone would be used for. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

III. New business

Dr. Gingrich stated that a Survey Monkey was sent to all members of the committee and that only 3 responses were received. Mr. Cackler stated that he did not receive the survey. Dr. Gingrich proposed that the PAPC meetings be moved to the 1st Monday of every month starting at 8:30A.M.-10:00 A.M. Mr. Cox stated that he was unable to commit to that date due to his work obligations. Mr. Cox offered to work with Ms. Keller to be certain that at least one of the Pharmacists would be available for each meeting. Mr. Cox felt that the 2nd Monday of the month would be a better time for him so long as he would be able to also attend the Pharmacy Board meeting by 10 a.m.

Dr. Gingrich moved to change the PAPC meeting dates to the 2nd Monday of the Month to start at 8:30 a.m. and to last no later than 10:00 a.m. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

Mr. Lestini informed the committee that the OAPA wants to legislatively change the formulary to use FDA approved drugs as the list of drugs for PA's to prescribe instead of the current formulary. Potential short term solutions to allow all new medication be added to the formulary and then reviewed by the committee for recommendations was discussed. It was determined that this would not be in the best interest of public safety and could add confusion to the prescribing ability of PA's if the default was to allow a medication and then it was subsequently removed. The committee will continue to monitor and work to improve its efficiency at reviewing medication requests and new medications and voiced understanding of the goal of Mr Lestini to seek legislative change during the current legislative cycle.

The Physician Assistant Policy Committee meeting was adjourned by Dr. Gingrich at approximately 3:00 p.m. on Tuesday, August 8, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on August 8, 2017.

Curtis Gingrich, MD, Chair, PAPC

PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES

November 13, 2017

The meeting was called to order at approximately 8:36 a.m. on Monday November 13, 2017.

Committee members present: Megan Keller, R.Ph.; Kindra Engle, D.O.; Robert Zaayer, PA-C; Scott Cackler, P.A.-C; Curtis Gingrich, M.D., and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, Tessie Pollock and Cathy Hacker.

Guest: Beth Adamson, OAPA.

I. Review of the September 11, 2017 minutes:

Dr. Steinbergh requested that the draft minutes be amended to reflect that she stated that the full Board is going to discuss legislation possibly doing away with the PAPC to facilitate the formulary through the PA/Scope of Practice Committee.

Dr. Steinbergh moved to approve the amended minutes. Mr. Cackler seconded the motion. all members voted aye. The motion carried.

II. Formulary Review

The committee reviewed the following new drugs to the market, as listed in Facts and Comparison, and recommended the following categories for these medications.

- Pasabiv: Antiparathyroid agent was added in the PI category.

Dr. Steinbergh moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

- Emflaza: it was noted that this medication is already on the formulary as a CTP may prescribe.

Dr. Steinbergh moved to approve this change. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

- Xermelo: an antidiarrhea agent was added in the PI category.

Mr. Zaayer moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

- Kisqali: an antineoplastic agent was added as a CTP may not prescribe.

Dr. Steinbergh moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

- Xadago: A MAO-B inhibitor was added to the PI category.

Dr. Steinbergh moved to approve this change. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

- Symproic: a peripheral opioid antagonist was added as follows: Under Gastrointestinal Drugs/Peripheral opioid antagonists/ created "Agents for opioid induced constipation" as Physician Initiated/Consulted. Symproic and Methylnaltrexone fall within this class.

Dr. Steinbergh moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

- Zejula: an antineoplastic agent was added as a CTP may not prescribe.

Dr. Steinbergh moved to approve this change. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

- Austedo: a VMAT2 inhibitor was added under Antiparkinson Agents as CTP May prescribe but physician initiated /consulted for Huntington Disease.

Dr. Steinbergh moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

- Ingrezza: a VMAT2 inhibitor was added under Antiparkinson Agents as CTP May prescribe but physician initiated /consulted for Huntington Disease.

Dr. Steinbergh moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

- Rydapt: an antineoplastic agent was added as a CTP may not prescribe.

Dr. Steinbergh moved to approve this change. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

- Alubbrig: an antineoplastic agent was added as a CTP may not prescribe.

Dr. Steinbergh moved to approve this change. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

- Nerlynx: an antineoplastic agent was added as a CTP may not prescribe.

Dr. Steinbergh moved to approve this change. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The following medications were tabled and are to be reviewed at the next PAPC meeting:

Tymlos
Radicava
Baxdela
Bevyxxa
Vosevi

III. New business

Tessi Pollock joined the meeting to announce that the Board is working on making the PA formulary a webpage so that it will be more user friendly. She requested that the committee make recommendations for the format.

Ms. Debolt presented a document that had recommendations for the format for physicians to request the committee to review medication changes on the formulary.

Dr. Steinbergh moved to approve the form. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The Physician Assistant Policy Committee meeting was adjourned by Dr. Gingrich at approximately 10:16a.m. on Monday November 13, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on November 13, 2017.

Curtis Gingrich, M.D., Chair, PASC



**PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES
December 11, 2017**

The meeting was called to order at approximately 8:35 a.m. on Monday December 11, 2017.

Committee members present: Megan Keller, R.Ph.; Jessica Thurman, P.A.-C; Joshua Cox, R.Ph.; Robert Zaayer, PA-C; Scott Cackler, P.A.-C; Curtis Gingrich, M.D., and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, and Cathy Hacker.

Guest: Beth Adamson, OAPA.

I. Review of the November 13, 2017 minutes:

Dr. Steinbergh moved to approve the minutes. Mr. Cackler seconded the motion. all members voted aye. The motion carried.

II. Formulary Review

The committee reviewed the following new drugs to the market, as listed in Facts and Comparison, and recommended the following categories for these medications.

- **Tymlos:** Antiparathyroid agent was added in the PI category.

Dr. Steinbergh moved to approve this change. Mr. Cackler seconded the motion. All members voted aye. The motion carried.

- **Radicava:** it was added to the formulary as a CTP may not prescribe.

Dr. Steinbergh moved to approve this change. Mr. Cox seconded the motion. All members voted aye. The motion carried.

- **Baxdela** a new antibiotic agent was added in the CTP may prescribe category.

Mr. Zaayer moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

- **Bevyxxa:** All Factor XA inhibitors were moved to the CTP may prescribe category.

Dr. Steinbergh moved to approve this change. Dr. Gingrich seconded the motion. All members voted aye. The motion carried.

- **Vosevi:** Anti HEP-C oral was added to the PI category.

Dr. Steinbergh moved to approve this change. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

- **Corlanor:** Was added to the CTP may prescribe category.
- Dr. Steinbergh moved to approve this change. Mr. Cackler seconded the motion. All members voted aye. The motion carried.

- **Entresto:** Was added to the CTP may prescribe category.

Dr. Steinbergh moved to approve this change Ms. Thurman seconded the motion. All members voted aye. The motion carried.

- **Kybella:** it was noted that this is already on the formulary as PI.

The committee discussed the need to revamp the formulary to more clearly address the esthetic injectable medications.

Mr. Cox agreed to work on a guidance document regarding the esthetic injectables for the website.

The following medications were tabled and are to be reviewed at the next PAPC meeting:

Hydroxurea
Respiratory tract agents

The committee will review all the antibacterial and aesthetic drugs as well as 8 new drugs to the market on the January 2018 agenda.

III. Rules review

Ms. Debolt presented the following rules for discussion:

4730-1-05 no changes to the rule
4730-2-04 removes the provisional prescribing language and clarifies the 500 hours of onsite supervision.
4730-2-05 clarifies how to apply for prescribing if the original license did not have it.

The Physician Assistant Policy Committee meeting was adjourned by Dr. Gingrich at approximately 10:11a.m. on Monday December 11, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on December 11, 2017.

Curtis Gingrich, M.D., Chair, PAPC